Energy News / Shareholders Foundation, Inc.

NASDAQ: ODT Investor Notice: Investigation over Potential Wrongdoing at Odonate Therapeutics, Inc.

Via: ReleaseWire

Updated 12:00 PM CST, Mon, January 28,2019

An investigation on behalf of investors in Odonate Therapeutics, Inc. (NASDAQ: ODT) shares over potential wrongdoing at Odonate Therapeutics, Inc. was announced.

San Diego, CA -- (SBWIRE) -- 01/28/2019 -- Certain directors of Odonate Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.

Investors who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Odonate Therapeutics, directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Diego, CA based Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. On December 6, 2017, Odonate Therapeutics, Inc. announced the pricing of its initial public offering ("IPO") of 6,250,000 shares of common stock at a public offering price of $24.00 per share for aggregate gross proceeds of approximately $150 million.

On February 14, 2018, Odonate Therapeutics, Inc announced its financial results for the three and twelve months ended December 31, 2017.

Odonate Therapeutics, Inc. reported that its Net Loss increased from $3.08 million in 2017 to $32.74 million in 2018

Shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) reached as high as $31.25 per share in March 5, 2018.

Since then shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) declined to as low as $11.63 per share on December 26, 2018.

On January 25, 2019, NASDAQ: ODT shares closed at $17.33 per share.

Those who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) have certain options and should contact the Shareholders Foundation.

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaq-odt-investor-notice-investigation-over-potential-wrongdoing-at-odonate-therapeutics-inc-1133541.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com